VGX-3100 HPV Cancer Vaccine Description
VGX-3100 is an investigational immunotherapy vaccine that includes DNA plasmids targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18.
VGX-3100 is a therapeutic DNA vaccine being investigated for the treatment of pre-cancers and cancers for the treatment of Recurrent Respiratory Papillomatosis or RRP. RRP is a rare condition that causes noncancerous tumor growths leading to life-threatening airway obstructions, and occasionally can progress to cancer.
RRP is generally broken down into two subtypes – the juvenile-onset form and the adult-onset form. Juvenile cases develop before the age of 12 and are generally more aggressive and recurring. Children tend to need surgical treatment more often than adults.
Currently, PRP is incurable and is mostly treated by surgery, which temporarily restores the airway. The tumor almost always recurs and the surgery must be repeated, often multiple times a year. RRP can severely impact the quality of life for those living with the disease.
"Inovio's investigational DNA medicine INO-3107 is designed to destroy and clear tumors caused by HPV 6 and 11 infections from the body exactly where they are hiding," said Jeffrey Skolnik, M.D., Inovio's Vice President of Clinical Development. "We believe this DNA medicine has the potential to provide people living with RRP a long-term, if not life-long, improvement in their disease, especially as an alternative to often successive and debilitating surgeries that may temporarily remove HPV growths from the airways but do not address the underlying recurring virus."
Inovio has 15 DNA medicine clinical programs currently in development focused on HPV-associated diseases, cancer, and infectious diseases. DNA medicines are medicines composed of optimized DNA plasmids, which are small circles of double-stranded DNA that are synthesized or reorganized by a computer sequencing technology and designed to produce a specific immune response in the body.
Inovio's DNA medicines deliver optimized plasmids directly into cells intramuscularly or intradermally using Inovio's proprietary hand-held smart device called CELLECTRA®. CELLECTRA uses a brief electrical pulse to open small pores in the cell reversibly to allow the plasmids to enter. Once inside the cell, the plasmids begin replicating, thereby strengthening the body's own natural response mechanisms.
Administration with the CELLECTRA device ensures that the DNA medicine is delivered directly into the body's cells, where it can go to work immediately mounting an immune response. Inovio's DNA medicines are not interfering with or changing in any way an individual's own DNA, which is the case with gene therapy or gene editing.
Inovio is an innovative biotechnology company focused on the discovery, development, and commercialization of its synthetic nucleic technology targeted against cancers and infectious diseases.
VGX-3100 HPV Cancer Vaccine Indication
VGX-3100 is designed to treat pre-cancers and cancers caused by human papillomavirus (HPV).
VGX-3100 HPV Cancer Vaccine Dosage
VGX-3100 is delivered intramuscularly followed by electroporation with CELLECTRA-5PSP delivery device.
HPV Vaccine Discounts
HPV vaccine discounts sponsored by GoodRx.
VGX-3100 HPV Cancer Vaccine News
March 26, 2020 - Inovio announced positive interim results from an open-label, Phase 2 study showing its lead DNA medicine candidate VGX-3100 to be safe and effective in treating men and women with anal dysplasia, also known as high grade squamous intraepithelial lesion (HSIL), a precancerous condition caused by high-risk human papillomavirus (HPV) types 16/18.
February 10, 2020 - Inovio Pharmaceuticals announced the U.S. FDA has accepted its Investigational New Drug application to evaluate its DNA medicine INO-3107 in a Phase 1/2 trial for the treatment of Recurrent Respiratory Papillomatosis.
July 8, 2019 - Inovio announced that it has completed enrollment in its Phase 2 trial with VGX-3100 in patients with precancerous lesions of the vulva or vulvar intraepithelial neoplasia (VIN). VGX-3100 is an immunotherapy that targets human papillomavirus (HPV) 16 and 18 and is being studied for the treatment of HPV-related precancerous lesions and the HPV infection that causes these lesions.
June 26, 2019 - Inovio has announced the completion of the target enrollment of 198 participants for its pivotal Phase 3 REVEAL 1 registration trial of VGX-3100, a novel DNA-based immunotherapy being tested to treat cervical dysplasia caused by human papillomavirus (HPV).
VGX-3100 HPV Cancer Vaccine Clinical Trials
Clinical Trial NCT03185013: Phase 3 Clinical Trial REVEAL 1 Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL. REVEAL 1 is designed to provide a one-year safety data for a minimum of 198 patients on VGX-3100.
Clinical Trial NCT03721978: Phase 3 Clinical Trial REVEAL 2 Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL. A confirmatory Phase 3 trial (REVEAL 2) is currently enrolling and is designed to provide a one-month safety data for a minimum of 198 patients.
Clinical Trial NCT03180684: Phase 2 Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL
Clinical Trial NCT03499795: Phase 2 VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High-Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2.